Where to Think ENBUMYST.
A short-term nasal option for diuretic management when oral therapy is inadequate, before escalation to IV therapy.
IMPORTANT SAFETY INFORMATION (Continued)
- ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, those with inadequate electrolyte intake, and the elderly. Abnormalities may include changes in blood electrolytes, BUN, glucose, and uric acid. Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid frequently during therapy.
- Bumetanide can cause dehydration and azotemia. Discontinue bumetanide if azotemia worsens and oliguria occurs during treatment of severe progressive renal disease.
- Tinnitus and hearing loss (usually reversible) have been reported with loop diuretics, including bumetanide. Reports indicate that ototoxicity is associated with rapid injection, severe renal impairment, use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
Please see more Important Safety Information below.
Watch: How to Use ENBUMYST
IMPORTANT SAFETY INFORMATION (Continued)
- Due to potential altered absorption, avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.
- Advise lactating women treated with ENBUMYST to monitor their breastfed infants for excessive urine output, dehydration, and lethargy.
- Most common adverse reactions reported in ENBUMYST studies were hypovolemia and headaches. Common adverse reactions reported with the use of oral bumetanide include muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).
Please see the full Prescribing Information and Patient Information for ENBUMYST
References:
1. ENBUMYST Prescribing Information. Corstasis Therapeutics Inc.